Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback